ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL
The chemotherapy-free regimen of ponatinib and blinatumomab achieved high response rates and reduced the need…
Browsing: ASH
ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS
The latest results of a Phase II study evaluating the addition of venetoclax to the…
ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax demonstrate robust efficacy and sustained response in older, unfit patients with previously untreated chronic lymphocytic leukaemia
New four-year follow-up results from the Phase 3 GLOW study (Abstract #93), were announced during…
ASH 2022: Next-generation targeted therapy zanubrutinib found superior to ibrutinib for CLL and SLL
The targeted drug zanubrutinib showed superior efficacy with fewer side effects than ibrutinib in the…
ASH 2022: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis
The immunotherapy blinatumomab was found to improve overall survival for patients with no measurable residual…
ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in newly diagnosed, transplant-ineligible MM
The Phase 3 MAIA study’s updated analyses reported progression-free survival, minimal residual disease negativity, overall…
ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities
During the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13…
ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back
Many children with ALL have a good outcome of their disease. After two years of chemotherapy…
ASH 2022: CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial
A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of…
ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and lenalidomide shows clinical activity in RRMM
According to the results of the phase 1b MajesTEC-2 study, the immune-based triplet therapy regimen of teclistamab-cqyv, a…